KEAP1 and ovarian cancer: Furthermore, overexpression of Nrf2, a regulator of an intracellular antioxidant response and is negatively regulated by Keap1, may be partially responsible to the aggressive biological behavior and poor clinical outcome due to its known effect of increased resistance to chemotherapeutic drugs as cisplatin in both endometrial and ovarian cancer cells [18, 20, 21].